trending Market Intelligence /marketintelligence/en/news-insights/trending/oz-tzf53vUGmYSEiaDxW5w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Antisense Therapeutics to raise A$1.6M for Duchenne muscular dystrophy drug

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Antisense Therapeutics to raise A$1.6M for Duchenne muscular dystrophy drug

Antisense Therapeutics Ltd. is looking to raise A$1.6 million in a share placement to fund its development of the ATL1102 drug for Duchenne muscular dystrophy.

Duchenne muscular dystrophy, or DMD, is a genetic disorder characterized by progressive muscle degeneration and weakness that could lead to death.

The company will issue 48,484,848 shares at 3 Australian cents apiece in the transaction. The placement is backed by Australian Ethical Investment and Platinum Asset Management, the company's major healthcare institutional shareholders.

Antisense Therapeutics plans to seek regulatory approval to conduct a phase 2b clinical study for ATL1102 among DMD patients in Europe.

XEC Partners is acting as lead manager in the placement.

Toorak, Victoria-based Antisense Therapeutics is engaged in the development and commercialization of antisense therapeutics to treat DMD, multiple sclerosis and acromegaly.